Spyre Therapeutics Says Both Doses Of SPY072 Met Statistical Significance On One Or More Endpoints In Phase 2 SKYWAY Rheumatoid Arthritis Sub-Study; Says Effect Did Not Meet Its Bar To Prioritize Monotherapy Development In RA